OncoSec Medical (ONCS) Receiving Somewhat Positive News Coverage, Report Finds

Media headlines about OncoSec Medical (NASDAQ:ONCS) have trended somewhat positive on Wednesday, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OncoSec Medical earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.360369796592 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of research analysts recently weighed in on the stock. HC Wainwright set a $4.00 price objective on shares of OncoSec Medical and gave the company a “buy” rating in a report on Wednesday, May 9th. Maxim Group set a $5.00 price objective on shares of OncoSec Medical and gave the company a “buy” rating in a report on Tuesday, May 8th. Finally, ValuEngine upgraded shares of OncoSec Medical from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. OncoSec Medical has a consensus rating of “Buy” and a consensus price target of $4.50.

OncoSec Medical stock traded down $0.03 during trading on Wednesday, reaching $1.48. The stock had a trading volume of 4,992 shares, compared to its average volume of 709,933. OncoSec Medical has a 52-week low of $0.88 and a 52-week high of $2.95. The company has a market capitalization of $75.16 million, a P/E ratio of -1.39 and a beta of 3.03.

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

Insider Buying and Selling by Quarter for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply